We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
AGI | LSE:AGI | London | Ordinary Share | IE00B0YT0Q82 | ORD EUR0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAGI
RNS Number : 4371Y
AGI Therapeutics plc
01 March 2012
AGI Therapeutics plc
("AGI" or the "Company")
Offer Update
01 March 2012
Aravis Therapeutics Limited ("Aravis") announced on 03 February 2012 that it had declared its Offer unconditional in all respects and it intended to exercise its rights under the provisions of Section 204 of the Irish Companies Act 1963 to acquire compulsorily all outstanding AGI Shares not acquired or agreed to be acquired pursuant to the Offer on the same terms as the Offer.
On 28 February 2012 Aravis issued statutory notices pursuant to section 204(1) of the Companies Act 1963 to those AGI Shareholders who had not yet validly accepted the Offer.
In accordance with section 204(1) of the Companies Act 1963, unless upon an application made to the Court by any AGI Shareholders who have not yet validly accepted the Offer, on or before 28 March 2012, the Court thinks fit to order otherwise, Aravis will be entitled and bound to compulsorily acquire the AGI Shares held by those Shareholders.
As notified pursuant to section 67 of the Companies Act 1990, as at 16 February 2012, Aravis holds 60,784,191 shares representing approximately 90.17 per cent of the issued share capital of the Company.
As announced on 03 February 2012, the last day of trading of AGI Shares on ESM and AIM will be close of business today and cancellation of admission to trading on ESM and AIM will take effect from 7.00 a.m. tomorrow, Friday 02 March 2012.
Capitalised terms used in this announcement shall bear the same meaning as in the Offer Document, unless the context requires otherwise.
Enquiries:
AGI Therapeutics plc Tel: +353 1 449 3254 David Kelly, CFO Tel: +353 1 679 6363 Davy Corporate Finance Financial adviser to AGI John Frain David Nangle Goodbody Corporate Finance Tel: +353 1 667 0420 Financial adviser to the Aravis Group Simon Howley Stephen Kane
This information is provided by RNS
The company news service from the London Stock Exchange
END
OUPBKCDDFBKDABB
1 Year AGI Chart |
1 Month AGI Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions